Unnamed: 0,title,date,stock,sentiment
1017882.0,10 Biggest Price Target Changes For Monday,2020-06-08 08:35:00-04:00,PLX,neutral
1017883.0,"HC Wainwright & Co. Maintains Buy on Protalix BioTherapeutics, Raises Price Target to $11",2020-06-08 06:35:00-04:00,PLX,neutral
1017884.0,Protalix BioTherapeutics shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.,2020-06-01 07:45:00-04:00,PLX,positive
1017885.0,"Protalix BioTherapeutics Q1 EPS $0.10 Beats $(0.30) Estimate, Sales $21.65M Beat $6.60M Estimate",2020-06-01 06:51:00-04:00,PLX,neutral
1017886.0,"Earnings Scheduled For June 1, 2020",2020-06-01 04:00:00-04:00,PLX,neutral
1017887.0,"The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight",2020-05-30 09:25:00-04:00,PLX,neutral
1017888.0,Protalix BioTherapeutics Reports Submission Of Biologics License Application For Pegunigalsidase Alfa For Treatment Of Fabry Disease,2020-05-28 06:53:00-04:00,PLX,neutral
1017889.0,32 Stocks Moving in Monday's Pre-Market Session,2020-05-11 07:18:00-04:00,PLX,neutral
1017890.0,"Protalix BioTherapeutics Announces Positive Topline Results from the BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease",2020-05-11 07:00:00-04:00,PLX,positive
1017891.0,98 Biggest Movers From Friday,2020-05-04 05:08:00-04:00,PLX,neutral
1017892.0,58 Stocks Moving In Friday's Mid-Day Session,2020-05-01 12:39:00-04:00,PLX,neutral
1017893.0,72 Biggest Movers From Yesterday,2020-05-01 05:29:00-04:00,PLX,neutral
1017894.0,61 Stocks Moving In Thursday's Mid-Day Session,2020-04-30 12:43:00-04:00,PLX,neutral
1017895.0,78 Biggest Movers From Yesterday,2020-04-15 04:45:00-04:00,PLX,neutral
1017896.0,55 Stocks Moving In Tuesday's Mid-Day Session,2020-04-14 12:52:00-04:00,PLX,neutral
1017897.0,86 Biggest Movers From Yesterday,2020-04-14 05:19:00-04:00,PLX,negative
1017898.0,Protalix 13G Filing From Alrov Properties/Technorov/Alfred Akirov Shows 9.99% Stake In Co.,2020-03-30 14:23:00-04:00,PLX,neutral
1017899.0,Protalix Biotherapeutics Announces Feasibility Study with Kirin Holdings on the Production of a Novel Complex Protein,2020-03-16 06:52:00-04:00,PLX,positive
1017900.0,90 Stocks Moving In Thursday's Mid-Day Session,2020-03-12 12:21:00-04:00,PLX,neutral
1017901.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,PLX,negative
1017902.0,"The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues",2020-03-08 16:14:00-04:00,PLX,negative
1017903.0,140 Biggest Movers From Friday,2020-03-02 04:43:00-05:00,PLX,neutral
1017904.0,86 Stocks Moving In Friday's Mid-Day Session,2020-02-28 12:19:00-05:00,PLX,negative
1017905.0,46 Stocks Moving in Friday's Pre-Market Session,2020-02-28 07:39:00-05:00,PLX,neutral
1017906.0,Protalix BioTherapeutics Presents Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease,2020-02-10 16:13:00-05:00,PLX,neutral
1017907.0,30 Stocks Moving in Monday's Pre-Market Session,2020-02-10 07:30:00-05:00,PLX,neutral
1017908.0,Protalix Reports Receipt Of Agreement Letter With Chiesi Farma For Initial Pediatric Study Plan For PRX-102 For Treatment Of Fabry Disease,2020-02-06 06:52:00-05:00,PLX,positive
1017909.0,30 Stocks Moving in Monday's Pre-Market Session,2020-02-03 07:30:00-05:00,PLX,neutral
1017910.0,82 Biggest Movers From Friday,2020-02-03 05:00:00-05:00,PLX,neutral
1017911.0,26 Stocks Moving in Wednesday's Pre-Market Session,2020-01-22 07:27:00-05:00,PLX,neutral
1017912.0,82 Biggest Movers From Yesterday,2020-01-22 04:18:00-05:00,PLX,neutral
1017913.0,80 Biggest Movers From Yesterday,2020-01-15 04:48:00-05:00,PLX,neutral
1017914.0,48 Stocks Moving In Tuesday's Mid-Day Session,2020-01-14 12:06:00-05:00,PLX,neutral
1017915.0,54 Biggest Movers From Yesterday,2020-01-09 04:47:00-05:00,PLX,neutral
1017916.0,40 Stocks Moving In Wednesday's Mid-Day Session,2020-01-08 12:15:00-05:00,PLX,neutral
1017917.0,27 Stocks Moving in Wednesday's Pre-Market Session,2020-01-08 07:58:00-05:00,PLX,neutral
1017918.0,50 Biggest Movers From Yesterday,2020-01-07 04:19:00-05:00,PLX,neutral
1017919.0,30 Stocks Moving In Monday's Mid-Day Session,2020-01-06 12:39:00-05:00,PLX,neutral
1017920.0,24 Stocks Moving in Monday's Pre-Market Session,2020-01-06 07:32:00-05:00,PLX,neutral
1017921.0,63 Biggest Movers From Tuesday,2020-01-02 05:05:00-05:00,PLX,neutral
1017922.0,38 Stocks Moving In Tuesday's Mid-Day Session,2019-12-31 12:18:00-05:00,PLX,neutral
1017923.0,58 Biggest Movers From Friday,2019-12-30 04:51:00-05:00,PLX,neutral
1017924.0,46 Stocks Moving In Friday's Mid-Day Session,2019-12-27 12:05:00-05:00,PLX,neutral
1017925.0,"Protalix BioTherapeutics Reports 1-For-10 Reverse Stock Split, Effective Dec. 19, 2019",2019-12-09 16:15:00-05:00,PLX,positive
1017926.0,Protalix BioTherapeutics shares are trading lower as a potential sell-off after the stock increased roughly 68% yesterday.,2019-11-19 15:15:00-05:00,PLX,positive
1017927.0,Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of Pegunigalsidase,2019-11-18 06:54:00-05:00,PLX,positive
1017928.0,"Protalix BioTherapeutics Q3 EPS $(0.02) Beats $(0.03) Estimate, Sales $14.248M Beat $11.6M Estimate",2019-11-07 09:46:00-05:00,PLX,neutral
1017929.0,"The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs",2019-11-07 07:18:00-05:00,PLX,negative
1017930.0,Protalix BioTherapeutics Announces Positive 12-Month Interim Data From BRIDGE Phase III Open Label Switch-Over Study Showing Pegunigalsidase Alfa For The Treatment Of Fabry Disease Was Well Tolerated,2019-10-17 07:42:00-04:00,PLX,positive
1017931.0,Protalix BioTherapeutics And Chiesi Group Complete Enrollment In Third Phase III Clinical Trial Of pegunigalsidase Alfa (PRXâ€‘102) For Treatment Of Fabry Disease,2019-09-24 07:03:00-04:00,PLX,neutral
1017932.0,"The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books",2019-09-04 07:08:00-04:00,PLX,positive
1017933.0,Protalix BioTherapeutics Receives Listing Deficiency Letter from NYSE American,2019-08-30 16:19:00-04:00,PLX,neutral
1017934.0,"The Daily Biotech Pulse: EC Approves Roche's Tecentriq For Breast Cancer, Trevena On Track For NDA Resubmission, Edap Earnings",2019-08-29 07:38:00-04:00,PLX,negative
1017935.0,Protalix BioTherapeutics Evaluating And Pursuing Alternatives,2019-08-22 08:47:00-04:00,PLX,neutral
1017936.0,110 Biggest Movers From Yesterday,2019-08-09 05:15:00-04:00,PLX,neutral
1017937.0,90 Stocks Moving In Thursday's Mid-Day Session,2019-08-08 12:50:00-04:00,PLX,neutral
1017938.0,Protalix BioTherapeutics shares are trading lower after the company reported worse-than-expected Q2 EPS results.,2019-08-08 09:15:00-04:00,PLX,neutral
1017939.0,"The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering",2019-08-08 07:11:00-04:00,PLX,neutral
1017940.0,"Protalix BioTherapeutics Q2 EPS $(0.05) Misses $(0.03) Estimate, Sales $12.247M Beat $11.75M Estimate",2019-08-08 06:46:00-04:00,PLX,negative
1017941.0,Protalix BioTherapeutics Announces Eyal Rubin CFO,2019-07-29 07:22:00-04:00,PLX,neutral
1017942.0,Protalix BioTherapeutics Completes Enrollment in the Phase III BRIGHT Clinical Trial of pegunigalsidase alfa (PRX 102) for the Treatment of Fabry Disease,2019-06-17 07:11:00-04:00,PLX,positive
1017943.0,"Protalix BioTherapeutics, Chiesi Report Will Apply For Accelerated Approval Of Pegunigalsidase Alfa For Treatment Of Fabry Disease In US",2019-06-06 07:21:00-04:00,PLX,positive
1017944.0,"Protalix Names Dror Bashan Pres, CEO",2019-05-21 07:10:00-04:00,PLX,neutral
1017945.0,Protalix BioTherapeutics S-3 Shows Registration For $100M Mixed Securities Offering,2019-03-29 16:17:00-04:00,PLX,positive
1017946.0,"Protalix BioTherapeutics Says it Will Restate its Q1, Q2 and Q3 2018 Financials to Recognize Revenue Which Was Not Previously Recognized",2019-03-18 07:11:00-04:00,PLX,neutral
1017947.0,"Earnings Scheduled For March 18, 2019",2019-03-18 03:56:00-04:00,PLX,neutral
1017948.0,"The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut",2019-02-07 08:08:00-05:00,PLX,neutral
1017949.0,Protalix BioTherapeutics Highlights Prelim. Data From BRIGHT Study Of pegunigalsidase alfa for the Treatment of Fabry Disease Will Be Featured at the 15th Annual WORLDSymposium,2019-02-05 07:13:00-05:00,PLX,positive
1017950.0,"The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs",2019-02-03 10:09:00-05:00,PLX,neutral
1017951.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018",2018-12-19 12:43:00-05:00,PLX,negative
1017952.0,Protalix BioTherapeutics Announces the Completion of Enrollment in the Phase III BRIDGE Clinical Trial of pegunigalsidase alfa for the Treatment of Fabry Disease,2018-12-17 07:17:00-05:00,PLX,neutral
1017953.0,"Protalix BioTherapeutics Q3 EPS $(0.10) Misses $(0.04) Estimate, Sales $663K Miss $7.98M Estimate",2018-11-07 08:09:00-05:00,PLX,negative
1017954.0,"The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie",2018-11-07 07:50:00-05:00,PLX,negative
1017955.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,PLX,neutral
1017956.0,"The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker",2018-10-05 08:35:00-04:00,PLX,positive
1017957.0,Protalix To Highlight Prelim. Data From BRIDGE Study Of Pegunigalsidase Alfa For Treatment Of Fabry Disease At 1st Canadian Symposium on Lysosomal Diseases,2018-10-05 07:04:00-04:00,PLX,positive
1017958.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-09-30 10:14:00-04:00,PLX,neutral
1017959.0,"Protalix Shares Open For Trade, Now Up 16% At $0.74/Share",2018-09-21 11:11:00-04:00,PLX,positive
1017960.0,"Protalix BioTherapeutics Shares Halted, News Pending",2018-09-21 10:52:00-04:00,PLX,positive
1017961.0,46 Biggest Movers From Yesterday,2018-07-25 04:03:00-04:00,PLX,neutral
1017962.0,Mid-Afternoon Market Update: NASDAQ Turns Negative; Whirlpool Shares Drop After Earnings Miss,2018-07-24 14:39:00-04:00,PLX,negative
1017963.0,34 Stocks Moving In Tuesday's Mid-Day Session,2018-07-24 12:28:00-04:00,PLX,neutral
1017964.0,Mid-Day Market Update: Crude Oil Up Over 1%; Protalix BioTherapeutics Shares Spike Higher,2018-07-24 12:05:00-04:00,PLX,negative
1017965.0,Benzinga Pro's 5 Stocks To Watch Today,2018-07-24 09:15:00-04:00,PLX,neutral
1017966.0,"Protalix BioTherapeutics Expands Partnership with Chiesi Farmaceutici to Include Exclusive U.S. Rights for the Development and Commercialization of PRX-102; Co. To Receive $25M Up Front, $20M In Development Costs, And $760M In Potential Milestones",2018-07-24 07:09:00-04:00,PLX,positive
1017967.0,Protalix BioTherapeutics Announces Additional Positive Results From Final Analysis Of The Phase II Clinical Trial Of OPRX-106 For Treatment Of Ulcerative Colitis,2018-06-05 07:03:00-04:00,PLX,positive
1017968.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,PLX,negative
1017969.0,UPDATE: Protalix Says 'Remaining Effective Enzyme in Blood Samples was more than Double for Pegunigalsidase Alfa (PRX-102) Compared to FabrazymeÂ® as a Result of Higher Inhibition of Neutralizing Antibodies Measured in Fabrazyme',2018-05-25 07:03:00-04:00,PLX,positive
1017970.0,Protalix BioTherapuetics Reports Poster Presentation On Baseline Characteristics For Fabry Disease Patients Screened In Phase II BALANCE Study Of Pegunigalsidase Alfa,2018-05-25 07:02:00-04:00,PLX,neutral
1017971.0,"Protalix BioTherapeutics Q1 EPS $(0.06) Beats $(0.09) Estimate, Sales $4.553M Beat $4.4M Estimate",2018-05-09 07:16:00-04:00,PLX,neutral
1017972.0,Benzinga Pro's 5 Stock To Watch Today,2018-03-13 08:12:00-04:00,PLX,neutral
1017973.0,Protalix BioTherapeutics' Phase 2 Trial of OPRX-106 for the Treatment of Ulcerative Colitis Meets Efficacy Endpoints,2018-03-13 07:09:00-04:00,PLX,neutral
1017974.0,"Protalix BioTherapeutics Reports FY EPS $(0.65) vs $(0.29) Est., Sales $19.24M vs $27.76M Est.",2018-03-06 07:38:00-05:00,PLX,neutral
1017975.0,25 Stocks Moving In Wednesday's Pre-Market Session,2018-01-31 08:16:00-05:00,PLX,neutral
1017976.0,Protalix BioTherapeutics' Pegunigalsidase Receives Fast Track Designation From the FDA,2018-01-31 07:33:00-05:00,PLX,neutral
1017977.0,Protalix Reports Pegunigalsidase Alfa Received Fast Track Designation,2018-01-31 07:32:00-05:00,PLX,neutral
1017978.0,35 Biggest Movers From Yesterday,2018-01-03 05:03:00-05:00,PLX,neutral
1017979.0,28 Stocks Moving In Tuesday's Mid-Day Session,2018-01-02 13:09:00-05:00,PLX,neutral
1017980.0,22 Stocks Moving In Tuesday's Pre-Market Session,2018-01-02 08:11:00-05:00,PLX,neutral
1017981.0,Protalix BioTherapeutics Reports 'Positive' Interim Data from Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis,2018-01-02 07:04:00-05:00,PLX,neutral
1017982.0,25 Stocks Moving In Wednesday's Mid-Day Session,2017-12-27 12:41:00-05:00,PLX,neutral
1017983.0,22 Stocks Moving In Wednesday's Pre-Market Session,2017-12-27 08:15:00-05:00,PLX,neutral
1017984.0,"A Peek Into The Markets: U.S. Stock Futures Mostly Flat Ahead Of Consumer Confidence, Pending Home Sales Data",2017-12-27 07:46:00-05:00,PLX,positive
1017985.0,Protalix BioTherapeutics' PRX-102 Granted Orphan Drug Designation by the European Commission,2017-12-27 07:30:00-05:00,PLX,positive
1017986.0,Protalix BioTherapeutics Completes Enrollment in Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis,2017-11-29 07:56:00-05:00,PLX,neutral
1017987.0,Protalix BioTherapeutics Presents 'Positive' Results from the Phase I/II Open-Label Extension Trial for PRX-102 at the New Horizons for Fabry Disease Conference,2017-11-27 07:06:00-05:00,PLX,neutral
1017988.0,28 Stocks Moving In Monday's Mid-Day Session,2017-11-13 12:47:00-05:00,PLX,neutral
1017989.0,28 Stocks Moving In Monday's Pre-Market Session,2017-11-13 08:06:00-05:00,PLX,neutral
1017990.0,Protalix BioTherapeutics Receives Positive Opinion for Orphan Designation for PRX-102 From COMP and EMA,2017-11-13 07:03:00-05:00,PLX,positive
1017991.0,"Protalix BioTherapeutics +38.46% Premarket @$0.90 After Co Reports Exclusive Ex-US Partnership With Chiesi Farmaceutici For Development, Commercialization Of PRX-102 For Treatment Of Fabry Disease",2017-10-18 07:49:00-04:00,PLX,positive
1017992.0,"UPDATE: Protalix Will Receive $25M Upfront, Added $25M In Development Costs, Added Up To $320M In Potential Regulatory, Commercial Milestone Payments",2017-10-18 06:56:00-04:00,PLX,neutral
1017993.0,UPDATE: Protalix Grants Chiesi Ex-US Rights To PRX-102,2017-10-18 06:55:00-04:00,PLX,positive
1017994.0,"Protalix BioTherapeutics Reports Entered Into Exclusive Ex-US Partnership With Chiesi Farmaceutici For Development, Commercialization Of PRX-102 For Treatment Of Fabry Disease",2017-10-18 06:54:00-04:00,PLX,positive
1017995.0,Protalix Offers Phase II Trial Results for Alidornase Alfa in CF: Showed 'meaningful decrease in efficacy parameters once treatment with alidornase alfa stopped further supporting alidornase alfa clinical efficacy',2017-06-07 07:32:00-04:00,PLX,positive
1017996.0,Protalix Reports FDA Approval for Operation of Current Facility as Multi-Product Facility,2017-06-01 07:35:00-04:00,PLX,positive
1017997.0,"Protalix BioTherapeutics Reports Q1 EPS $(0.48) vs $(0.09) in Same Qtr. Last Year, Sales $2.889M vs $2.55M Est.",2017-05-10 07:52:00-04:00,PLX,neutral
1017998.0,Protalix Reports FDA Investigational New Drug Clearance to Commence Once-Monthly Dosing Study of pegunigalsidase alfa,2017-05-09 07:46:00-04:00,PLX,neutral
1017999.0,Protalix BioTherapeutics Reports Preclinical Results Showing Positive Effect of PRX-102 on Small-Fiber Neuropathy in Fabry Disease Models Compared to Commercially Available Enzyme Replacement Therapies,2017-04-18 07:31:00-04:00,PLX,positive
1018000.0,7 Biggest Price Target Changes For Monday,2017-04-17 09:52:00-04:00,PLX,neutral
1018001.0,"Rodman & Renshaw Reiterates Buy On Protalix BioTherapeutics, Raises Price Target To $5",2017-04-17 07:08:00-04:00,PLX,neutral
1018002.0,10 Biggest Mid-Day Losers For Wednesday,2017-04-12 13:57:00-04:00,PLX,negative
1018003.0,Adam Feuerstein Tweets: $PLX Cystic Fibrosis Drug Study Results Worsen Over Time â€”> thestreet.com/story/14083744â€¦,2017-04-12 09:21:00-04:00,PLX,negative
1018004.0,Protalix Offers Results from Phase II Trial of AIR DNase for Treatment of Cystic Fibrosis: Show 'Number of Clinically Relevant Parameters Suggest Improved Lung Function',2017-04-12 07:31:00-04:00,PLX,positive
1018005.0,"Protalix Reports FY16 EPS $(0.29) vs $0.61 in FY15, Sales $9.199M",2017-03-16 08:01:00-04:00,PLX,neutral
1018006.0,18 Biggest Mid-Day Gainers For Monday,2017-02-13 12:30:00-05:00,PLX,neutral
1018007.0,Protalix Bio Therapeutics Gives 2017 Objectives,2017-01-09 06:09:00-05:00,PLX,neutral
1018008.0,15 Biggest Mid-Day Losers For Tuesday,2017-01-03 12:49:00-05:00,PLX,negative
1018009.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-01-03 08:11:00-05:00,PLX,neutral
1018010.0,Protalix BioTherapeutics Reports Positive Results from Phase II Clinical Trial of alidornase alfa,2017-01-03 07:32:00-05:00,PLX,positive
1018011.0,Protalix Receives Confirmation Of $24M Order of alfataliglicerase To Treat Brazilian Patients With Gaucher,2016-12-27 07:32:00-05:00,PLX,positive
1018012.0,Protalix BioTherapeutics Enrolls Last Patient in AIR DNase Phase 2 Trial,2016-12-22 07:32:00-05:00,PLX,neutral
1018013.0,Protalix BioTherapeutics Receives Letter Detailing Intended Purchases of Approximately $24 Million of alfataliglicerase By Brazilian Ministry Of Health to Treat Gaucher Patients in Brazil,2016-12-14 07:31:00-05:00,PLX,positive
1018014.0,"European Crohn's, Colitis Organisation Issues New Statement Support a Switch to Biosimilar from Reference Product in Inflammatory Bowel Disease",2016-12-09 10:18:00-05:00,PLX,positive
1018015.0,Protalix BioTherapeutics Enrolls First Patient in Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis,2016-11-30 07:30:00-05:00,PLX,neutral
1018016.0,"Protalix BioTherapeutics Reports Q3 EPS $(0.07) vs $(0.10) Est., Sales $7.118M vs $4.364M in Same Qtr. Last Year",2016-11-09 08:09:00-05:00,PLX,neutral
1018017.0,Protalix Reports Results from Phase I/II Trial of PRX-102 for Treatment of Fabry Disease at SSIEM; Co. Recruiting Patients for Phase III Pivotal Trial,2016-09-07 07:03:00-04:00,PLX,neutral
1018018.0,"UPDATE: Protalix Biotherapeutics Says PRX-102 Was Well Tolerated; Majority of Adverse Events were Mild, Moderate",2016-08-10 07:34:00-04:00,PLX,negative
1018019.0,UPDATE: Protalix Reports Added Data from Phase I/II Trial for PRX-102 for Treatment of Fabry Disease: Improvements of Stabilization in Efficacy Were Demonstrated Across All Disease Parameters,2016-08-10 07:34:00-04:00,PLX,positive
1018020.0,Protalix BioTherapeutics Releases Additional Positive Data from its Phase I/II Clinical Trial for PRX-102 for the Treatment of Fabry Disease,2016-08-10 07:33:00-04:00,PLX,positive
1018021.0,"Protalix Reports Q2 EPS $(0.11) vs $(0.08) Est., Sales $1.769M vs $1M Est.",2016-08-08 16:35:00-04:00,PLX,neutral
1018022.0,Protalix BioTherapeutics Reports First Patient Dosed in the AIR DNase Phase II Clinical Trial for Cystic Fibrosis,2016-07-07 07:31:00-04:00,PLX,neutral
1018023.0,Protalix BioTherapeutics Starts PRX-102 Global Phase III Clinical Trial of Fabry Disease to Support United States and European Filings,2016-06-06 07:07:00-04:00,PLX,positive
1018024.0,Protalix BioTherapeutics Initiates PRX-102 Phase III Study,2016-06-06 07:05:00-04:00,PLX,neutral
1018025.0,"Protalix Bio Therapeutics Q1 EPS ($0.09) vs ($0.08) est, Revenue $679K vs $1.1M est",2016-05-09 07:26:00-04:00,PLX,neutral
1018026.0,Benzinga's Top Initiations,2016-04-04 09:47:00-04:00,PLX,positive
1018027.0,"Rodman & Renshaw Initiates Coverage on Protalix BioTherapeutics at Buy, Announces $3.50 PT",2016-04-04 07:03:00-04:00,PLX,neutral
1018028.0,Protalix BioTherapeutics Reports FY15 EPS $0.61 vs. Est. $0.68,2016-03-08 07:34:00-05:00,PLX,neutral
1018029.0,Protalix BioTherapeutics Presents Positive Six and Twelve Month Interim Clinical Data on PRX-102 for the Treatment of Fabry Disease at the 12th Annual WORLDSymposiumâ„¢ 2016,2016-03-03 07:09:00-05:00,PLX,positive
1018030.0,"Protalix BioTherapeutics Reports Q3 EPS $(0.04) vs. Est. $(0.08), Rev. $4.3M vs. Est. $5M",2015-11-09 16:30:00-05:00,PLX,neutral
1018031.0,Protalix BioTherapeutics Reports Positive Long Term Data on PRX-102 for Fabry Disease,2015-10-19 07:33:00-04:00,PLX,positive
1018032.0,Morning Market Gainers,2015-10-13 09:46:00-04:00,PLX,neutral
1018033.0,Protalix BioTherapeutics Sells Share In ELELYSO Partnership & 6% Stake In Protalix To Pfizer For $46M,2015-10-13 07:32:00-04:00,PLX,positive
1018034.0,Protalix BioTherapeutics to Explore Non Alcoholic Steato Hepatitis (NASH) as an Indication for Its PRX 106 Oral Anti TNF,2015-10-05 08:02:00-04:00,PLX,negative
1018035.0,US Stock Futures Point To Higher Open,2015-09-09 07:22:00-04:00,PLX,neutral
1018036.0,Protalix BioTherapeutics Announces Positive Phase I/II Interim Clinical Data on the 1mg/kg Cohort of PRX-102 for Fabry Disease,2015-09-09 07:08:00-04:00,PLX,positive
1018037.0,Protalix BioTherapeutics Reports Positive Phase I/II Interim Clinical Data on the 1mg/kg Cohort of PRX-102 for Fabry Disease,2015-09-09 07:02:00-04:00,PLX,positive
1018038.0,"Protalix Reports Q2 Net Loss of $0.05/Share, Sales $3.8M",2015-08-10 16:32:00-04:00,PLX,negative
1018039.0,"Protalix Reports Phase I Clinical Study Results for PRX-106 Showed Favorable Safety, Tolerability Profile Activity",2015-08-03 07:34:00-04:00,PLX,positive
1018040.0,Protalix BioTherapeutics Announces AIR DNase(TM) Data Presented at the 38th European Cystic Fibrosis Conference,2015-06-12 07:30:00-04:00,PLX,neutral
1018041.0,"Protalix Reports Q1 Loss of $0.06/Share vs Loss of $0.08/Share Est., Sales $4.4M vs $8.2M Est.",2015-05-07 17:10:00-04:00,PLX,negative
1018042.0,"Protalix Biotherapeutics Reports Q1 EPS $0.06 Vs Est Loss $0.08, May Not COmpare, Revs $4.39M Vs Est $8.20M",2015-05-07 16:33:00-04:00,PLX,negative
1018043.0,"Jefferies Initiates Coverage on Protalix BioTherapeutics at Buy, Announces $2.60 PT",2015-04-23 06:36:00-04:00,PLX,neutral
1018044.0,"Protalix BioTherapeutics Reports FY14 EPS $(0.30) vs. Est $(0.27), Rev. $10.5M vs. Est. $31.09M",2015-03-12 16:33:00-04:00,PLX,neutral
1018045.0,Protalix BioTherapeutics Presents Positive Phase I/II Interim Clinical Data on PRX-102 for Fabry Disease at  WORLD Symposium,2015-02-12 07:33:00-05:00,PLX,positive
1018046.0,Protalix BioTherapeutics Completes Enrollment in Phase I/II Clinical Trial of PRX-102 for Fabry Disease,2015-02-02 07:02:00-05:00,PLX,neutral
1018047.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4,2015-01-13 11:34:00-05:00,PLX,neutral
1018048.0,"Pharmaceuticals, Therapeutics And A Retailer On The Move Thursday Morning",2015-01-08 09:00:00-05:00,PLX,neutral
1018049.0,Protanx Announces Positive Interim Efficacy For PRX-102 Trial,2015-01-08 07:06:00-05:00,PLX,positive
1018050.0,Protalix Unveils New Strategy for Accelerated Growth: Expecting to Initiate Phase III Trial for PRX 102 in Early '16,2015-01-05 07:27:00-05:00,PLX,positive
1018051.0,Protalix Biotherapeutics Shares Move Higher; Mention as IBIO Sympathy Play,2014-10-13 09:43:00-04:00,PLX,positive
1018052.0,Protalix BioTherapeutics Namess Moshe Manor as President and CEO,2014-09-29 05:06:00-04:00,PLX,neutral
1018053.0,"UPDATE: Protalix Shares Spike Higher on FDA Approval of Pediatric Indication for ELELYSO(TM) for Injection, for IV Use for Treatment of Type 1 Gaucher Disease",2014-08-28 13:18:00-04:00,PLX,positive
1018054.0,"Protalix Shares Spike Higher on FDA Approval of Pediatric Indication for ELELYSO(TM) for Injection, for IV Use for Treatment of Type 1 Gaucher Disease",2014-08-28 13:17:00-04:00,PLX,positive
1018055.0,"Amended 13D Filing from Bio-Cell on Protalix Shows Deal to Seek Buyers for 4.4M Shares, Will Sell Shares at $2.47/Share",2014-08-28 10:25:00-04:00,PLX,positive
1018056.0,3 Pharma Companies That Could Deliver Breakthroughs In 'Plantibody' Technology,2014-08-24 20:08:00-04:00,PLX,neutral
1018057.0,Protalix Biotherapeutics Reports Q2 Loss of $0.07/Share vs $0.07/Share Loss Est.,2014-08-07 16:41:00-04:00,PLX,negative
1018058.0,Stocks Hitting 52-Week Lows,2014-07-01 10:20:00-04:00,PLX,negative
1018059.0,"Protalix Biotherapeutics Reports New Data on ELELYSO, Oral GCD Will Be Presented at European Working Group on Gaucher Disease",2014-06-23 07:35:00-04:00,PLX,neutral
1018060.0,Protalix Initiates Phase II PRX-112 Study,2014-06-18 07:31:00-04:00,PLX,neutral
1018061.0,Protalix Announces ELELYSO Approved in Canada,2014-05-30 07:30:00-04:00,PLX,positive
1018062.0,"Protalix Reports ELELYSO Approved in Australia for Treatment of Gaucher Disease in Adults, Pediatric Patients",2014-05-22 07:33:00-04:00,PLX,positive
1018063.0,Protalix Announces Elelyso Approved in Austrailia,2014-05-22 07:33:00-04:00,PLX,positive
1018064.0,Protective Life Corporation Reports Q1 Revenue of $6.70M vs $1.06B Est,2014-05-08 16:32:00-04:00,PLX,neutral
1018065.0,Protalix Announces Data on Oral antiTNF to be Presented at Digestive Disease Week 2014 Meeting,2014-04-23 08:33:00-04:00,PLX,neutral
1018066.0,"Protalix BioTherapeutics, Inc. Reports Q4 EPS of $(0.12) vs $(0.03) Est",2014-03-13 16:43:00-04:00,PLX,neutral
1018067.0,Protalix Biotherapeutics Announces Oral GCD Data Will Be Presented at WORLD Symposium 2014,2014-02-12 07:32:00-05:00,PLX,neutral
1018068.0,"RF Lafferty & Co. Initiates Coverage on Protalix BioTherapeutics, Inc. at Buy",2014-01-24 11:17:00-05:00,PLX,neutral
1018069.0,"Protalix Offers Update on Health Canada Evaluation, Says Manufacturing Facility Utilizing ProCellEx Deemed Acceptable by EMA, FDA, IMH, ANVISA, TGA",2014-01-23 16:35:00-05:00,PLX,positive
1018070.0,"JP Morgan Initiates Coverage on Protalix BioTherapeutics, Inc. at Overweight, Announces $7.00 PT",2013-10-21 06:48:00-04:00,PLX,neutral
1018071.0,"Protalix Reports Oral GCD Well Toleratead, Active Enzyme Detected in Blood",2013-10-14 07:31:00-04:00,PLX,positive
1018072.0,"Protalix Reports Closing of $69M Offering of Convertible Notes, Will Receive $66.8M in Net Proceeds from Offering",2013-09-18 10:34:00-04:00,PLX,neutral
1018073.0,Protalix BioTherapeutics Announces Proposed $60M Offering of Convertible Notes,2013-09-11 16:07:00-04:00,PLX,neutral
1018074.0,"(OPTIONS): Protalix June $5.00 Puts Trade 2,500 Times Over 120 OI, August $5.00 Puts Trade 2,000 Times Over 99 OI",2013-05-14 13:11:00-04:00,PLX,neutral
1018075.0,"(OPTIONS): Protalix November OTM 5.00 Puts Trade 2,000 Times Over an OI of 3",2013-04-29 11:04:00-04:00,PLX,neutral
1018076.0,"Protalix Says COFEPRIS, Public Health Institute of Chile Grant Approval to UPLYSO for Type 1 Gaucher Disease",2013-04-29 07:34:00-04:00,PLX,positive
1018077.0,Protalix Expects Phase 1 Trial of PRX112 Complete in Q3,2013-04-02 07:33:00-04:00,PLX,neutral
1018078.0,"UPDATE: Pfizer, Protalix Receive ANVISA Approval for UPLYSO in Brazil",2013-03-18 14:18:00-04:00,PLX,positive
1018079.0,"Pfizer, Protalix Says Brazil Approvs Uplyso",2013-03-18 14:17:00-04:00,PLX,neutral
1018080.0,Protalix Says New Clinical Data on ELELYSO Will Be Presented at WORLD Symposium,2013-02-13 07:33:00-05:00,PLX,neutral
1018081.0,"Benzinga's M&A Chatter for Tuesday February 5, 2013",2013-02-05 17:48:00-05:00,PLX,neutral
1018082.0,"Mid-Afternoon Market Update: Markets Edge Toward Record Highs, Arch Coal Falls Further",2013-02-05 15:57:00-05:00,PLX,neutral
1018083.0,"Mid-Day Market Update: Markets Rally Further, Clean Harbors Drops on CFO Controversy ",2013-02-05 13:33:00-05:00,PLX,positive
1018084.0,"Protalix Says Reviewing Partnering, Other Alternatives",2013-02-05 11:48:00-05:00,PLX,neutral
1018085.0,Protalix Exploring Strategic Review,2013-02-05 11:47:00-05:00,PLX,neutral
1018086.0,Protalix Spokesperson Declines Comment on Pfizer Headline,2013-02-05 09:22:00-05:00,PLX,neutral
1018087.0,"Calcalist Reporting Pfizer Said to Have Expressed Interest in Protalix, Co. Could Be Valued at Around $1B",2013-02-05 09:06:00-05:00,PLX,positive
1018088.0,Protalix BioTherapeutics Signs Clinical Development Agreement With Pfizer for ELELYSO,2012-12-06 07:49:00-05:00,PLX,positive
1018089.0,Protalix Signs Clinical Development Pact for Elelyso with Pfizer,2012-12-06 07:46:00-05:00,PLX,neutral
1018090.0,"UPDATE: Jefferies & Company Reiterates Hold Rating, Lowers PT on Protalix BioTherapeutics",2012-11-09 08:59:00-05:00,PLX,negative
1018091.0,"Jefferies & Company Maintains Protalix BioTherapeutics at Hold, Lowers PT from $6 to $5.50",2012-11-09 07:32:00-05:00,PLX,negative
1018092.0,Protalix BioTherapeutics Receives FDA IND Clearance to Initiate a Phase I/II Study of Fabry Disease Patients With PRX-102,2012-08-13 07:47:00-04:00,PLX,neutral
1018093.0,"UPDATE: Aegis Capital Reiterates Hold Rating, Lowers PT on Protalix BioTherapeutics",2012-07-16 11:34:00-04:00,PLX,negative
1018094.0,"Aegis Capital Maintains Protalix BioTherapeutics at Hold, Lowers PT from $7 to $5.50",2012-07-16 07:31:00-04:00,PLX,negative
1018095.0,Protalix BioTherapeutics Announces New Clinical Data on taliglucerase alfa Presented at the 10th Annual European Working Group on Gaucher Disease Meeting ,2012-07-02 07:30:00-04:00,PLX,neutral
1018096.0,"Benzinga's Downgrade Summary for June 25, 2012",2012-06-25 15:29:00-04:00,PLX,neutral
1018097.0,UPDATE: Wells Fargo Downgrades Protalix BioTherapeutics to Market Peform on EU Challenges for Elelyso  ,2012-06-25 10:43:00-04:00,PLX,positive
1018098.0,Wells Fargo Downgrades Protalix BioTherapeutics from Outperform to Market Perform,2012-06-25 09:32:00-04:00,PLX,positive
1018099.0,EMA Adopts Opinion on Taliglucerase Alfa Marketing Authorization Application ,2012-06-22 08:33:00-04:00,PLX,positive
1018100.0,Protalix Receives a $25 Million Milestone Payment for U.S. Approval of ELELYSO,2012-06-11 07:30:00-04:00,PLX,positive
1018101.0,"Option Alert: Protalix Biotherapeutics Put Volume at 1,146% of Average",2012-05-02 10:19:00-04:00,PLX,positive
1018102.0,Protalix BioTherapeutics Spiking Lower on Heavy Volume; Currently at $7.24,2012-05-02 09:41:00-04:00,PLX,negative
1018103.0,Protalix BioTherapeutics Rises 29% Pre-Market on FDA Approval for Elelyso,2012-05-02 07:28:00-04:00,PLX,positive
1018104.0,"FDA Approves Protalix, Pfizer Drug To Treat Gaucher Disease",2012-05-01 16:16:00-04:00,PLX,positive
1018105.0,Protalix BioTherapeutics Gets FDA Approval for Elelyso,2012-05-01 16:16:00-04:00,PLX,positive
1018106.0,Protalix Biotherapeutics Spikig Lower on Heavy Volume,2012-03-19 15:38:00-04:00,PLX,negative
1018107.0,Protalix Biotherapeutics Sold 5.18M Shares at $5.25 per Share; Will Use Shares to Fund Trials and Research,2012-02-22 17:26:00-05:00,PLX,positive
1018108.0,Notable Call Options Activity in Protalix BioTherapeutics,2012-02-17 13:46:00-05:00,PLX,neutral
1018109.0,Protalix BioTherapeutics Announces the Pricing of Public Offering of Common Stock,2012-02-16 08:41:00-05:00,PLX,neutral
1018110.0,Protalix BioTherapeutics Announces Proposed Public Offering of Common Stock; No Amount Given ,2012-02-15 16:16:00-05:00,PLX,negative
1018111.0,FDA Delays Protalix's Drug Decision; Investors Feel Sick,2011-12-06 12:23:00-05:00,PLX,negative
1018112.0,Morning Market Losers,2011-12-06 09:57:00-05:00,PLX,negative
1018113.0,"FDA Extends Taliglucerase Alfa PDUFA Date to May 1, 2012",2011-12-06 07:30:00-05:00,PLX,positive
1018114.0,"Pluristem Therapeutics' CEO Letter to Shareholders: ""Current Data Suggest that Approx 20% of CLI patients will Die Within the first 6-12 Months""",2011-11-22 08:03:00-05:00,PLX,negative
1018115.0,Protalix's Acetylcholinesterase Demonstrates Potential Role in the Treatment of Parkinson's Disease  ,2011-11-10 06:52:00-05:00,PLX,neutral
1018116.0,Pluristem Therapeutics CEO Letter to Shareholders ,2011-09-16 06:55:00-04:00,PLX,neutral
1018117.0,"Protalix BioTherapeutics' Taliglucerase Alfa Phase III Results Published in Blood, the Journal of the American Society of Hematology  ",2011-09-08 08:06:00-04:00,PLX,neutral
1018118.0,Protalix BioTherapeutics Announces FDA Accepts for Review Complete Response Resubmission for Taliglucerase Alfa and Assigns PDUFA Date,2011-08-17 07:48:00-04:00,PLX,positive
1018119.0,Protalix Submits Reply to FDA Complete Response Letter for Taliglucerase Alfa and Reports Top-Line Results from the Company's Switchover Trial ,2011-08-01 08:03:00-04:00,PLX,neutral
1018120.0,Protalix To File Drug Approval Request To FDA within Days -Globes,2011-07-21 10:24:00-04:00,PLX,positive
1018121.0,"Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer",2011-06-01 12:13:00-04:00,PLX,positive
1018122.0,Hapoalim Cutting Ocverage On Multitude Of Names,2011-06-01 11:48:00-04:00,PLX,negative
1018123.0,Biotech/ Biodefense Sector Trading Alert,2011-05-05 13:36:00-04:00,PLX,positive
1018124.0,Biotech/ Biodefense Sector Trading Alert,2011-04-08 12:14:00-04:00,PLX,positive
1018125.0,Protalix BioTherapeutics Announces Proposed Public Offering of Common Stock ,2011-03-17 16:07:00-04:00,PLX,neutral
1018126.0,Protalix BioTherapeutics Trading Significantly Lower Today (PLX),2011-02-25 09:59:00-05:00,PLX,negative
1018127.0,FDA Issues Complete Response Letter for Taliglucerase Alfa New Drug Application ,2011-02-25 07:58:00-05:00,PLX,neutral
1018128.0,Pfizer Inks Deal With Theraclone - Analyst Blog,2011-01-20 11:01:00-05:00,PLX,neutral
1018129.0,Pfizer Inks Deal With Theraclone - Analyst Blog,2011-01-20 10:45:00-05:00,PLX,neutral
1018130.0,Wells Fargo Initiates Coverage On PLX With An Outperform Rating And A Valuation Range Of $12-14,2010-12-10 10:37:00-05:00,PLX,positive
1018131.0,Canadian Approval for Shire Drug - Analyst Blog,2010-12-09 12:03:00-05:00,PLX,positive
1018132.0,Canadian Approval for Shire Drug - Analyst Blog,2010-12-09 11:18:00-05:00,PLX,positive
1018133.0,Pfizer/Protalix Seek EU Approval - Analyst Blog,2010-11-29 09:30:00-05:00,PLX,positive
1018134.0,Pfizer/Protalix Seek EU Approval - Analyst Blog,2010-11-29 04:12:00-05:00,PLX,positive
1018135.0,"UBS Reiterates Coverage On (VFC, SBUX, PLX, KED, HAIN, GEL, KO, AFL, CSX)",2010-10-14 11:35:00-04:00,PLX,neutral
1018136.0," Protalix BioTherapeutics And PROLOR Biotech May Rise On ""Protein Acquistion""  (PBTH, PLX)",2010-09-08 07:59:00-04:00,PLX,neutral
1018137.0,Genzyme Rejects Sanofi Offer - Analyst Blog,2010-08-31 06:21:00-04:00,PLX,negative
1018138.0,European Approval for Shire Drug - Analyst Blog,2010-08-27 17:33:00-04:00,PLX,positive
1018139.0,Protalix BioTherapeutics Up Strong This Morning (PLX),2010-08-25 09:54:00-04:00,PLX,positive
1018140.0,"Benzingaâ€™s News Roundup (MGA, ASML, PCS, PLX, MRNA, ROSG)",2010-01-13 08:05:00-05:00,PLX,neutral
1018141.0,"Benzingaâ€™s News Roundup (SPLS, PFE, LINE, ED, STT)",2009-12-01 09:26:00-05:00,PLX,neutral
1018142.0,"New 52-Week High Stocks (RCKY, TTEC, UFS, PRGO, PLX)",2009-11-02 11:33:00-05:00,PLX,neutral
